Brief: Ocuphire Pharma To Present New Interim Masked Safety Data For Oral Apx3330 In Diabetics At Annual Macula Society Meeting
08/06/2022 13:59
June 8 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE TO PRESENT NEW INTERIM MASKED SAFETY DATA FOR
ORAL
APX3330 IN DIABETICS AT ANNUAL MACULA SOCIETY MEETING
* OCUPHIRE PHARMA INC - OF 103 DIABETIC SUBJECTS ENROLLED IN
24-WEEK ZETA-1 PHASE 2B TRIAL, 70% HAVE COMPLETED 12 OR MORE
WEEKS
* OCUPHIRE PHARMA INC - TOPLINE RESULTS WITH FIRST-IN-CLASS
NON-INVASIVE RETINAL CANDIDATE APX3330 EXPECTED IN SECOND HALF
OF 2022
Source text for Eikon: ID:nGNX9vl7xl
Further company coverage: OCUP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data